ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Senate Appropriations Report Language On NCI, NIH Budgets

September 20, 1996

Tasigna Wins New Indication For CML; Jevtana Approved For Prostate Cancer

June 18, 2010

Lymphoblastoid If Test Shows Toxicity Not From Impurity, Investigator Says

August 8, 1980

NCI-Approved Clinical Trials

July 30, 2010

In Brief: Waxman Now Key House Health Figure; Kennedy Subcommittee Beefed Up with Top Democrats

February 9, 1979

Giaccone Joins Georgetown Lombardi Center

February 22, 2013